Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
On 30 January 2020, the World Health Organization (WHO) declared the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic a public health emergency of international concern. The viral outbreak led in turn to an exponential growth of coronavirus disease 2019 (COVID-19) cases, that is, a multiorgan disease that has led to more than 6.3 million deaths worldwide, as of June 2022. There are currently few effective drugs approved for treatment of SARS-CoV-2/COVID-19 patients. Many of the compounds tested so far have been selected through a drug repurposing approach, that is, by identifying novel indications for drugs already approved for other conditions. We here present an up-to-date review of the main Food and Drug Administration (FDA)-approved drugs repurposed against SARS-CoV-2 infection, discussing their mechanism of action and their most important preclinical and clinical results. Reviewed compounds were chosen to privilege those that have been approved for use in SARS-CoV-2 patients or that have completed phase III clinical trials. Moreover, we also summarize the evidence on some novel and promising repurposed drugs in the pipeline. Finally, we discuss the current stage and possible steps toward the development of broadly effective drug combinations to suppress the onset or progression of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Therapeutic advances in respiratory disease - 16(2022) vom: 03. Jan., Seite 17534666221132736 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taibe, Noha Samir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 15.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/17534666221132736 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347966535 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347966535 | ||
| 003 | DE-627 | ||
| 005 | 20231226035100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17534666221132736 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347966535 | ||
| 035 | |a (NLM)36282077 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taibe, Noha Samir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a On 30 January 2020, the World Health Organization (WHO) declared the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic a public health emergency of international concern. The viral outbreak led in turn to an exponential growth of coronavirus disease 2019 (COVID-19) cases, that is, a multiorgan disease that has led to more than 6.3 million deaths worldwide, as of June 2022. There are currently few effective drugs approved for treatment of SARS-CoV-2/COVID-19 patients. Many of the compounds tested so far have been selected through a drug repurposing approach, that is, by identifying novel indications for drugs already approved for other conditions. We here present an up-to-date review of the main Food and Drug Administration (FDA)-approved drugs repurposed against SARS-CoV-2 infection, discussing their mechanism of action and their most important preclinical and clinical results. Reviewed compounds were chosen to privilege those that have been approved for use in SARS-CoV-2 patients or that have completed phase III clinical trials. Moreover, we also summarize the evidence on some novel and promising repurposed drugs in the pipeline. Finally, we discuss the current stage and possible steps toward the development of broadly effective drug combinations to suppress the onset or progression of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a baricitinib | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a molnupiravir | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Kord, Maimona A |e verfasserin |4 aut | |
| 700 | 1 | |a Badawy, Mohamed Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Shytaj, Iart Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Elhefnawi, Mahmoud M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in respiratory disease |d 2007 |g 16(2022) vom: 03. Jan., Seite 17534666221132736 |w (DE-627)NLM185567118 |x 1753-4666 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g day:03 |g month:01 |g pages:17534666221132736 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17534666221132736 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |b 03 |c 01 |h 17534666221132736 | ||